Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N N dimethyltryptamine - Psilera

Drug Profile

N N dimethyltryptamine - Psilera

Alternative Names: DMT intranasal - Psilera; DMT patch - Psilera; N,N-dimethyltryptamine - Psilera

Latest Information Update: 19 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Psilera
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules; Tryptamines; Vascular disorder therapies
  • Mechanism of Action 5-HT1 serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psychiatric disorders; Social phobia

Most Recent Events

  • 14 Sep 2022 Psilera receives patent allowance for DMT and psilacetin transdermal patch formulations in USA
  • 18 Mar 2022 Psilera announces intention to submit IND for Social phobia (Psilera pipeline, March 2022)
  • 15 Mar 2022 Psilera website explains about serotonin receptors (5-HT) but doesn't specify about its role as agonist or antagonist hence taken MOA Serotonin-1-receptor-modulators as discussed with SME - Shohini; STR addition req sent; matched properties with the THES
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top